Sanofi (SNY) Cash from Restructuring (2009 - 2026)

Sanofi (SNY) has 18 years of Cash from Restructuring data on file, last reported at -$371.1 million in Q1 2026.

• Quarterly Cash from Restructuring fell 22.93% year-over-year to -$371.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.6 billion (down 0.72% YoY) and the FY2024 annual result came in at -$841.0 million, up 12.05% from the prior year.
• Cash from Restructuring climbed to -$371.1 million in Q1 2026 per SNY's latest filing, from -$913.8 million in the prior quarter.
• The five-year high for Cash from Restructuring was -$301.9 million in Q1 2025, with the low at -$1.1 billion in Q4 2022.
• Average Cash from Restructuring over 5 years is -$640.1 million, with a median of -$405.2 million recorded in 2022.
• Year-over-year, Cash from Restructuring sank 37.66% in 2022 and advanced 20.48% in 2023.
• Sanofi's Cash from Restructuring stood at -$1.1 billion in 2022, then gained by 20.48% to -$913.5 million in 2023, then dropped by 9.03% to -$995.9 million in 2024, then climbed by 8.25% to -$913.8 million in 2025, then surged by 59.39% to -$371.1 million in 2026.
• Business Quant data shows SNY's Cash from Restructuring at -$371.1 million in Q1 2026, -$913.8 million in Q4 2025, and -$301.9 million in Q1 2025.